GYRE
Gyre Therapeutics, Inc. Common StockstockNASDAQ
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.49 | 2026-09-28 | -4.75% | 2.424 |
| 1M | 6.86 | 2026-09-04 | +4.00% | 0.792 |
| 3M | 7.26 | 2026-07-06 | -1.73% | 1.463 |
| 6M | 7.12 | 2026-04-06 | +0.20% | 0.890 |
| 1Y | 7.34 | 2025-10-06 | -2.80% | 1.123 |
| 2Y | 13.47 | 2024-10-04 | -47.04% | — |
Gyre Therapeutics, Inc. Common Stock (NASDAQ:GYRE) stock price today is $7.13, and today's volume is 163,747. GYRE is up 1.917% today. The 30 day average volume is 154,402. GYRE market cap is $756.47M with 106.03M shares outstanding.